Antiblastic chemotherapy in the presence of abdominal aorta aneurysm (AAA): guidelines.
Concomitant neoplasm and abdominal aortic aneurysm (AAA) is not a rare clinical association and can pose problems if antiblastic treatment is required. The literature shows lack of consensus owing to the fact that AAA can modify the liquid load and the hemodynamic setting so that chemotherapy toxicity profile becomes important and hydration overload increases the AAA-breakage risk. We have analyzed the possibility of treatment with a non-critical water load related chemotherapy in these patients, and if it can offer benefit it terms of overall survival (OS) and quality of life (QL). We concluded that in chemotherapy the presence of AAA does not have to be excluded first, if such critical parameters such as response to chemotherapy AAA-breakage risk vascular and extravascular toxicity do not compromise the OS and QL of the patients.
Lauro
S
S
Dipartimento di Medicina Sperimentale e Patologia, Università La Sapienza, Rome, Italy.
Lanzetta
G
G
Bria
E
E
Trasatti
L
L
Gelibter
A
A
Vecchione
A
A
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D017544:Aortic Aneurysm, Abdominal / Q000150:complications* / Q000473:pathology; D001019:Aortic Rupture / Q000517:prevention & control; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007674:Kidney Diseases / Q000150:complications; D009369:Neoplasms / Q000150:complications* / Q000188:drug therapy; D017410:Practice Guidelines as Topic; D012307:Risk Factors; D014652:Vascular Diseases / Q000139:chemically induced
D000970:Antineoplastic Agents